Fecal transplant with immunotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery.
- Your cancer worsened after treatment with immunotherapy (with or without chemotherapy).
- You received antibiotics within 60 days before your first immunotherapy dose and within 42 days after it.
- You are at least 18 years old.
- You have a good enough performance status (able to care for yourself, up to spending less than half the day in bed).
- You are not pregnant, breastfeeding, and agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mix of high and low dose radiation along with chemotherapy and immunotherapy for people with locally advanced non-small cell lung cancer. It aims to see if this combination can improve treatment outcomes.
This study tests whether giving a fecal microbiota transplant (a stool transplant from a healthy donor or someone who responded well to immunotherapy) together with the immunotherapy drug tislelizumab can help people with advanced or metastatic non-small cell lung cancer (NSCLC). It's for patients whose cancer grew after prior immunotherapy.
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
This trial tests if a fecal transplant from immunotherapy responders can help treat stage II-III non-small cell lung cancer patients who haven't had treatment yet.
This trial tests a combination of fecal microbiota transplantation (FMT), immunotherapy, and chemotherapy as a first treatment for advanced non-small cell lung cancer that does not have a driver gene mutation. The goal is to see if adding FMT can help the immune system fight the cancer better.
This trial tests if giving a special capsule of donated bacteria (fecal transplant) alongside standard immunotherapy helps shrink tumors in people with advanced melanoma. It aims to see if adding the bacteria can make the immune therapy work better.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.